Abstract: A low-calcium silicate cement, comprising: based on the total mass of oxides as 1, 50-60% of calcium oxide, 30-45% of silica, 2-6% of alumina, and 1-4% of iron oxide. A preparation method of the low-calcium silicate cement comprises: subjecting raw materials to crushing, joint grinding and uniform mixing to obtain a low-calcium silicate cement raw meal; calcining the above low-calcium silicate cement raw meal at 1050-1300° C. for 30-90 min, and cooling to obtain low-calcium silicate cement clinker; and levigating the above low-calcium silicate cement clinker till a specific surface area is 400-500 m2/Kg, thereby obtaining a low-calcium silicate cement.

Abstract: A concrete mix having sand, fine aggregates, binder, fibers, and various admixtures is provided. The mix has a consistency from S2 to SF3, a compressive strength in the range of 30-80 MPa and a ductility represented by fc, ffl, fR1 and fR3 values, wherein the concrete mix contains at least 390 Kg of binder, the concrete mix has a paste volume of 300-600 liters, the concrete mix contains at least two systems of fibers and a general admixture system that is composed of at least 2 sub-admixture systems.

Abstract: Various methods for making material capable of forming structural composites are disclosed. For example, a particular method may include growing an amount of cyanotic organisms, separating cell walls of the cyanotic organisms from internal portions of the cyanotic organisms to form a purified algae extract, the purified algae extract being from the internal portions of the cyanotic organisms, and applying an effective amount of alkaline water to the purified algae extract to form a balanced algae extract having little or no chemical reactivity, wherein a pH of the alkaline water is a function of a pH of the purified algae extract.

Abstract: Disclosed is a construction material composition including a matrix predominantly containing an aluminum silicate compound, such as a metakaolin, and an alkaline activation solution. The composition is contains less than 10 wt. % cement or clinker and in that the metakaolin is a metakaolin obtained via flash calcination. The reaction between the components is carried out at a temperature less than 30° C. The method for manufacturing the construction material includes mixing the composition with various elements such as granulates, plant fibers, unfired clay, and expanding agents. It is particularly of use in producing floor, wall, or roof coating elements, prefabricated construction elements, or insulation, adhesive, or inorganic sealant modules.

Abstract: The invention relates to a composition for preparing a green body for the manufacture of a refractory carbon-bonded product, a method for preparing such a green body and a green body prepared by such a method.

Abstract: Disclosed are ceramic bodies comprised of composite cordierite-mullite-aluminum magnesium titanate (CMAT) ceramic compositions having high cordierite-to-mullite ratio and methods for the manufacture of same.

Abstract: A precursor material is provided for additive manufacturing of a low-density, high-porosity ceramic part. The precursor material comprises a body of refractory fibers and a binder in admixture with the body of refractory fibers. The precursor material further comprises a viscosity control additive in admixture with the binder and the body of refractory fibers to provide an overall mixture with a viscosity between about 0.3 centipoise and about 150,000 centipoise. The overall mixture can be extruded through a nozzle to manufacture the low-density, high porosity ceramic part. The precursor material is produced by obtaining a refractory fiber slurry, and adding a viscosity control additive to the slurry to provide the slurry with a viscosity that is suitable for extrusion through a nozzle to manufacture a low-density, high-porosity ceramic part.

Abstract: The disclosure describes in some examples a technique that includes aligning a plurality of carbon preform segments in a staggered arrangement, where each carbon preform segment of the plurality carbon preform segment includes a carbon body including at least one of a plurality of carbon fibers or a carbon foam, and a silicon-based mixture including silicon particles. The techniques may include heating the staggered arrangement to react the silicon particles with the carbon body to bond the plurality of carbon preform segments together and form a ceramic matrix composite component.

Abstract: The invention comprises a method of curing concrete. The method comprises placing a concrete cylinder in an insulated container having a sufficient quantity of water therein so that the concrete cylinder is submerged in and surrounded by the water and selectively adding heat to the quantity of water in an insulated container, so that the temperature of the quantity of water follows a predetermined temperature profile. Apparatus for performing the method is also disclosed.

Abstract: Disclosed is a fibrous solid substrate in pellet form suitable for use in agriculture. The fibrous solid substrate in pellet form is obtained from spent biomass material following an anaerobic fermentation and biogas production. Further disclosed is a method for cultivating fungal cells and/or spores using said fibrous solid substrate in pellet form. Also disclosed are methods for upgrading spent biomass material from a biogas production unit to fertilizer products, fibers and substrate for biogas.

Abstract: A housing for a worm farm includes a composting cavity that, in use of the housing, is to contain worms, bedding material and/or organic waste, the composting cavity being defined by a floor having openings through which castings can pass, and one or more side walls that extend around the floor. A support structure supports the floor and the side walls above a ground surface. A cover locates on the side walls and extend over the composting cavity, and is movable to enable access to the composting cavity. A castings receptacle is movable between an operative position and at least one displaced position.

Abstract: A method of making light olefins is described. The method involves producing an alkyne in a pyrolysis process. The alkyne is catalytically hydrogenated in a hydrogenation zone to produce a product stream containing a light olefin. A byproduct stream from the pyrolysis process comprises carbon oxide and hydrogen. The byproduct stream is treated to convert the carbon oxide and the hydrogen to an oxygenated product in a carbon oxide conversion zone, which can then be converted to an olefin in an oxygenate to olefin process.

Abstract: The present specification relates to a double spiro structure compound and an organic light emitting device including the same.

Abstract: Provided herein are methods and systems for converting natural gas, and specifically methane, into higher-value oxycarbon products, such as methanol, methyl formate, and formic acid. The natural gas is introduced into an aqueous solution with hydroxyl radicals and reacted in ambient conditions to form the desired products in the presence of a metal catalyst. The methods described herein overcome the “over-activation” dilemma of prior art methods that lead to the formation of undesirable carbon oxide compounds. Methods and apparatus for forming hydrogen peroxide via electrolysis and for forming hydroxyl radicals from the hydrogen peroxide via reaction with ferrous ions are also provided.

Abstract: Disclosed herein are embodiments of multicyclic compounds and methods of making such compounds. The disclosed methods reduce step-counts in the synthesis of complex targets, while reducing costs and waste streams.

Abstract: The invention provides an improved process for preparing Ethacrynic acid of formula I, including the steps of: (a) reacting 4-butyryl-2,3-dichloro-phenoxy acetic acid of formula II with dimethylamine or its salt to obtain [2,3-dichloro-4-[2-dimethylaminomethyl butyryl phenoxy acetic acid of formula III or its salt; (b) hydrolysing [2,3-dichloro-4-[2-dimethylaminomethyl butyryl phenoxy acetic acid hydrochloride of formula III obtained in step a) with t-butyl amine to obtain t-butyl amine salt of Ethacrynic acid; (c) acidifying the t-butyl amine salt of Ethacrynic acid formed in step b) to obtain Ethacrynic acid of formula I; and(d) optionally purifying the obtained Ethacrynic acid with a solvent mixture of alkyl acetate and hydrocarbon solvent. The invention also provides crystalline t-butylamine salt of Ethacrynic acid and process thereof. Also provide compound Ethacrynic acid having a purity of greater than or equal to 99% and a composition including the compound.

Abstract: The present disclosure provides polymorphic forms of sodium benzoate with a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2? of approximately 5.9, 30.2, and 31.2 degrees; or a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2? of approximately 3.7, 5.9, and 26.6 degrees. Also provided herein are methods of preparing the polymorphic forms of sodium benzoate and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, or Alzheimer's disease).

Abstract: Described herein are processes and apparatus for the high purity and high concentration recovery of multivalent products via continuous ion exchange from aqueous solutions for further down-stream purification.

Abstract: The present invention includes novel polycationic amphiphilic compounds useful as antimicrobial agents. The present invention further includes novel polymers of polycationic amphiphilic compounds useful as antimicrobial agents. The present invention further includes methods useful for removing microorganisms and/or biofilm-embedded microorganisms from a surface. The present invention further includes compositions and methods useful for preventing or reducing the growth or proliferation of microorganisms and/or biofilm-embedded microorganisms on a surface.

Abstract: The invention relates to compounds useful in treating conditions associated with voltage-gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns compounds (e.g., compounds according to any of Formulas (I)-(XIII) and in particular Formula (X), and Compounds (1)-(236) of Table 1) that are useful in treatment of a variety of diseases and conditions.

Abstract: Compounds of Formula (Ia) wherein R is a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl, a C1-C5 substituted or unsubstituted alkyl or —NR?R?, Q is C(O), O, NR?, S, S(O)2, C(O)2(CH2)p Y is C(O), O, NR?, S, S(O)2, C(O)2(CH2)p Z is H or C1-C4 alkyl, R? is H, C(O), S(O)2, C(O)2, a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl or a C1-C6 substituted or unsubstituted alkyl, when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C6-C12 heteroaryl, —NR?R? or COOZ, which have diagnostic and therapeutic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition. Radiolabels can be incorporated into the structure through a variety of prosthetic groups attached at the X amino acid side chain via a carbon or hetero atom linkage.

Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.

Abstract: The present invention relates to a process for the synthesis of cysteamine or a salt thereof.

Abstract: An object of the present invention is to provide a method for producing a fluorinated organic compound with a high yield without using carbon tetrachloride in view of the fact that the production of a fluorinated organic compound with a sufficient yield was impossible for a hitherto-known method that uses a fluorinating agent that contains IF5-pyridine-HF alone. Another object of the present invention is to provide a fluorinating reagent that is capable of achieving this object. The present invention provides a composition comprising (1) IF5 and (2) an aprotic solvent (with the proviso that carbon tetrachloride is excluded), wherein the aprotic solvent is contained in an amount within a range of 50 mass ppm to 20 mass %.

Abstract: The invention concerns a continuous process for manufacturing methionine by alkaline hydrolysis of methionine hydantoin in aqueous phase, removing NH3 and CO2 of the hydrolysis medium, and neutralizing the obtained methioninate salt, according to which, after removal of NH3 and CO2, the hydrolysis reaction medium is concentrated to precipitate Na2CO3, said Na2CO3 being separated then recycled for alkaline hydrolysis, the latter being carried out in the presence of NaOH and Na2CO3.

Abstract: The disclosed technology relates to water soluble, or partially water soluble, chain transfer agents for preparing water soluble polymers by Reversible Addition-Fragmentation Chain Transfer (“RAFT”) polymerization in an aqueous medium.

Abstract: The present invention provides novel process for the preparation of the ?1-adrenoceptor antagonists, Silodosin and its pharmaceutically acceptable salts indoline compounds, utilizing derivatives of Formula 1 and salts thereof.

Abstract: The present invention relates to N-alkylaryl-5-oxyaryl-octadihydrocyclopent[c]pyrrole negative allosteric modulators of NR2B receptors useful in the treatment of neurological diseases having the Formula I where R1, R2, L1, L2, X, Y, and Y? are described therein. In an aspect, compounds of formula I are described and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or stereoisomers thereof wherein: L1 is straight or branched C1-C5 alkyl optionally substituted with one or more substituents selected from the group consisting of OH, ORIO, NH2, NHRio, and N(Rlo)(Rio?) provided that no more than one oxygen or nitrogen is attached to any carbon.

Abstract: The present invention relates to crystalline forms of cabozantinib phosphoric acid salt and cabozantinib hydrochloric acid salt and to a method for their preparation. Furthermore, the invention relates to pharmaceutical compositions comprising said crystalline forms and their use as anti-cancer medicaments. Cabozantinib, i.e. N-{4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl}-N?-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide is represented by the chemical structure: Formula.

Abstract: The invention provides dimeric quinacrine derivatives and related compounds and compositions, methods of treatment and syntheses. The novel compounds exhibit unexpected anticancer activity and are useful in the treatment of a variety of autophagy-related disorders.

Abstract: The present invention relates to a N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.

Abstract: The present invention relates to a process comprising reacting p-fluorobenzaldehyde, 4-methyl-3-oxopentanenitrile and urea in a first reaction mixture comprising a first organic solvent, thereby obtaining an intermediate mixture comprising an oxo-pyrimidine-carbonitrile; and oxidizing the oxo-pyrimidine-carbonitrile by contacting the intermediate mixture or organic extract with an organic hydroperoxide, thereby obtaining a hydroxyl-pyrimidine carbonitrile.

Abstract: Sodium channel blockers represented by the formula: are provided where the structural variables are defined herein. The invention also includes a variety of compositions, combinations and methods of treatment using these inventive sodium channel blockers.

Abstract: The invention provides novel compounds and compositions comprising a 5-HT2B antagonist of formula I: and related methods for treating a person having a disorder characterized by undesirable 5-HT2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.

Abstract: Described are methods for purifying a 5-nitrotetrazolate solution with a copper(II) modified cation exchange resin. The method can be performed as a stand-alone system or as a system integrated into a continuous flow reactor.

Abstract: Compositions and methods are for inducing, promoting or otherwise facilitating pain relief. More particularly, sub-doses of nitric oxide donors are used in the therapeutic management of vertebrate animals including humans, for the prevention or alleviation of pain, especially neuropathic pain. In some applications of the method, nitric oxide donors can be administered by any suitable route so as to provide concentrations of NO that are about ½ to 10?15 times those known to induce vasodilation in normal circulations.

Abstract: The present invention relates to a novel process for the preparation of pantolactone by reaction of hydroxypivalaldehyde cyanohydrin in a phase separation process.

Abstract: This invention relates to malienated derivatives made from maleic anhydride, functionalized monomers, and one or more additional reagents, e.g., an oxygen-containing reagent (e.g., alcohol, polyol), a nitrogen-containing reagent (e.g., amine, polyamine, aminoalcohol), a metal and/or a metal compound. The invention relates to lubricants, functional fluids, fuels, dispersants, detergents and functional compositions (e.g., cleaning solutions, food compositions, etc.

Abstract: Novel bacterial inhibitors comprising benzofuran derivatives, and methods of bacterial inhibition using the inhibitors are disclosed. The inhibitors may inhibit, for example, mycobacteria, including M. tuberculosis, by inhibition of the Pks13 enzyme. The inhibitors cmat exhibit potent whole cell and in vivo efficacy against M. tuberculosis.

Abstract: The present invention provides compounds represented by formula (1A), or pharmaceutically acceptable salts. Compounds represented by formula (1A), or pharmaceutically acceptable salts thereof, wherein A1 and A2 are identical or different, and each independently —C(?O) B, —C(?O)CR3AR3BB, —CO2B, —C(?S)OB, —CONR3CB, —C(?S)NR3CB, a hydrogen atom, or the like, wherein A1 and A2 are not both hydrogen atoms, wherein B is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, an optionally substituted 3- to 12-membered cyclic amino group, or a group represented by the following formula (B), wherein the 3- to 12-membered monocyclic or polycyclic heterocyclic group and the 3- to 12-membered cyclic amino group have at least one or more secondary nitrogen atoms in the ring; R1 is a hydrogen atom or the like; R2A, R2B, R2C, and R2D are identical or different, and each independently a hydrogen atom or the like; and R8 is alkyl. wherein * denotes a bonding position.

Abstract: The present invention relates to a novel polymorph of nilotinib hydrochloride (Form X), to processes for its preparation, to pharmaceutical compositions containing the same and to its use in medicine.

Abstract: The application relates to compounds of Formula (I?): which modulate the activity of a kinase (e.g., STK4), a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease or disorder associated with the modulation of a kinase, such as STK4.

Abstract: Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

Abstract: The present invention provides a diaminopyrimidine derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharmaceutical composition comprising the same, and a use thereof. The diaminopyrimidine derivative or its pharmaceutically acceptable salt functions as a 5-HT4 receptor agonist, and therefore can be usefully applied for preventing or treating dysfunction in gastrointestinal motility, one of the gastrointestinal diseases, such as gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, or diabetic gastric atony.

Abstract: The invention relates to new selective FYN kinase inhibitors of Formula (I), pharmaceutical compositions containing them, and their use for the pharmacological treatment of pain and arthritis, including osteoarthritis and rheumatoid arthritis.

Abstract: This invention relates to novel, deuterated forms of VX-661 and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating cystic fibrosis.

Abstract: This invention is directed to compounds, which are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.

Abstract: The invention provides dihydro-2H-benzo[b] [1,4]oxazine sulfonamide and related compounds, pharmaceutical compositions, methods of promoting ROR? activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.

Abstract: Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

Abstract: This disclosure relates to the field of molecules having pesticidal utility against pests in phyla Nematoda, Arthropoda, and/or Mollusca, processes to produce such molecules and intermediates used in such processes, compositions containing such molecules, and processes of using such molecules against such pests. These molecules may be used, for example, as nematicides, acaricides, insecticides, miticides, and/or molluscicides. This document discloses molecules having the following formula (“Formula One” and “Formula Two”).